1090-1091 / 1578
Individual Patient Data Meta-Analysis: NSCLC
757 NSCLC patients with 1-5 synchronous or metachronous mets
Median OS
26 months
, 1-year OS 70.2%, and 5-year
OS 29.4%
Surgery
was the commonest treatment modality for both the primary
(n=635,
83.9%
) and for metastases (n=339,
62.3%
)
Recursive Partitioning Analysis for risk groups;
Low-risk
: metachronous metastase (5-year OS 48%)
Intermediate risk
: synchronous metastases, N0 disease (5-year OS 36%)
High-risk
: synchronous metastases, N1/N2 disease (5-year OS 14%)
Ashworth A, Clin Lung Cancer 2014